ClinicalTrials.gg
Active, not recruitingNCT05676931EDGE-LungUpdated Jun 1, 2026

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

A Phase 2 interventional study of Domvanalimab and Quemliclustat in Advanced Non-Small Cell Lung Cancer, sponsored by Gilead Sciences. Active, not recruiting at 53 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
342nd of 2,995
400 · median 56
Started
2023
with 163 others
Phase 2
1,078 of 3,368
119 open now
Primary completion
2027-12
later than 506 of 892 live
Registered
2,793rd of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 342nd largest by planned enrollment of the 2,995 interventional ones that give a count, is one of 164 that started in 2023, is one of 1,078 in phase 2, reaches primary completion later than 506 of the 892 other live ones, and was the 2,793rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.

Read the detailed description

The study includes multiple substudy arms (Substudy A, B, C), which will evaluate immunotherapy-based combinations.

03

Conditions studied

  • Advanced Non-Small Cell Lung Cancer

Keywords

  • Advanced Non-Small Cell Lung Cancer
  • Domvanalimab
  • Zimberelimab
  • Quemliclustat
  • Anti-TIGIT antibody
  • Anti-PD-1 antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented Stage IV , NSCLC
  • performance status (ECOG PS) of 0 to 1
  • At least one measurable target lesion per v1.1.
  • Adequate organ function
  • Participants must be willing to provide adequate tumor tissue

Exclusion criteria

Exclusion Criteria:

  • Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Product(s) (IPs) hazardous
  • Use of any against infectious diseases within 28 days of first dose of IP(s).
  • Use of supra-physiologic doses of (> 10 mg/day of oral prednisone or equivalent) or medications ≤ 14 days before the initiation of study treatment (absorbable topical corticosteroids are not excluded).
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Any active disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    A1: Domvanalimab + Zimberelimab

    Domvanalimab and Zimberelimab, both administered by IV infusion

    Drug: Domvanalimab · Drug: Zimberelimab

  • Experimental
    A2: Domvanalimab + Zimberelimab

    Domvanalimab and Zimberelimab, both administered by IV infusion

    Drug: Domvanalimab · Drug: Zimberelimab

  • Experimental
    A3: Quemliclustat + Zimberelimab

    Quemliclustat and Zimberelimab, both administered by IV infusion

    Drug: Quemliclustat · Drug: Zimberelimab

  • Experimental
    B1: Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy

    Quemliclustat, zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion

    Drug: Quemliclustat · Drug: Zimberelimab · Drug: Platinum-Based Doublet

  • Experimental
    B2: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy

    Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion

    Drug: Domvanalimab · Drug: Zimberelimab · Drug: Platinum-Based Doublet

  • Experimental
    B3: Domvanalimab + Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy

    Domvanalimab, Quemliclustat, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion

    Drug: Domvanalimab · Drug: Quemliclustat · Drug: Zimberelimab · Drug: Platinum-Based Doublet

  • Experimental
    B4: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy

    Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion

    Drug: Domvanalimab · Drug: Zimberelimab · Drug: Platinum-Based Doublet

  • Experimental
    B5: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy

    Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion

    Drug: Domvanalimab · Drug: Zimberelimab · Drug: Platinum-Based Doublet

  • Experimental
    C1: Quemliclustat + Zimberelimab + Docetaxel

    Quemliclustat, Zimberelimab, and Docetaxel, all administered by IV infusion

    Drug: Quemliclustat · Drug: Zimberelimab · Drug: Docetaxel

  • Experimental
    C2: Domvanalimab + Zimberelimab + Docetaxel

    Domvanalimab, Zimberelimab, and Docetaxel, all administered by IV infusion

    Drug: Domvanalimab · Drug: Zimberelimab · Drug: Docetaxel

Interventions

  • Administered as specified in the treatment arm

  • Administered as specified in the treatment arm

  • Administered as specified in the treatment arm

  • Administered as specified in the treatment arm

  • DrugPlatinum-Based Doublet

    Administered as specified in the treatment arm

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: Up to 58 months

  2. The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to 58 months

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: From date of first dose until the date of death due to any cause (approximately 58 months)

  2. Progression-free Survival (PFS) as determined by the Investigator according to RECIST v1.1

    Time frame: Up to 58 months

  3. Disease Control Rate (DCR)

    Time frame: Up to 58 months

  4. Duration of response (DoR) as determined by the Investigator according to RECIST v1.1

    Time frame: Up to 58 months

  5. Investigational study treatments peak plasma or serum concentration (Cmax)

    Time frame: Up to 58 months

  6. Investigational study treatments time of peak concentration (Tmax)

    Time frame: Up to 58 months

  7. Investigational study treatments area under the plasma or serum concentration versus time curve (AUC)

    Time frame: Up to 58 months

  8. Percentage of biologic treatment-emergent antidrug-antibody (ADA)-positive participants and ADA-negative participants

    Time frame: Up to 58 months

07

Study locations

53 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 58 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2022
First posted
Jan 9, 2023
StartActual
Feb 21, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05676931
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 9, 2023
Start date
Feb 21, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Domvanalimab · Quemliclustat

Start the discussion